NO961888L - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser - Google Patents
Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaserInfo
- Publication number
- NO961888L NO961888L NO961888A NO961888A NO961888L NO 961888 L NO961888 L NO 961888L NO 961888 A NO961888 A NO 961888A NO 961888 A NO961888 A NO 961888A NO 961888 L NO961888 L NO 961888L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- therapeutic use
- peptidyl compounds
- metal proteinases
- matrix metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forbindelse med formel (l), hvori R1 er Cj^alkyl, C,_ 6alkenyl, aryl, (C^alkyl) aryl eller C^alkyl-AR9 hvor A er O, NR9 eller S(O)m, hvor m = 0-2, og hver R9 er H, C1_4alkyl, aryl eller (C1_4alkyl) -aryl; R2 er H eller Cx_6alkyl; enten er R4 H eller C^.galkyl eventuelt substituert med amino(NH2), aryl- amino, beskyttet amino, aryl, di(C1_6alkyl) amino, 6alkyl)amino, C02H, beskyttet karboksyl, karbamoyl, 6alkyl)karbamoyl eller di (C^.galkyl) -karbamoyl, og R5 er H eller C^alkyl, eller NR4R5 er pyrrolidono, piperidino eller morfolino; R6 er eventuelt substituert C3_6cykloalkyl, C3_6- cykloalkenyl, C1_6alkyl, benzyl, (C1_6alkoksy) benzyl, benzyl- oksybenzyl eller 3-indolylmetyl; Alk er C^.galkyl eller C2_ 5alkenyl, og n = O eller 1; R7 er H eller R10CO hvor R10 er C±_ 4alkyl, (C1_4alkyl)-aryl, C3_6cykloalkyl, (C3_6cykloalkyl) - C1_4alkyl, C2_6alkenyl eller (C2_6alkenyl)aryl; og R8 er H, C^ 4alkyl, (C1_4alkyl)aryl eller aryl; eller et salt, solvat eller hydrat derav. Slike forbindelser kan anvendes for å behandle tilstander i forbindelse med metalloproteinase, TNF og/eller annen aktivitet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939323165A GB9323165D0 (en) | 1993-11-10 | 1993-11-10 | Compounds |
PCT/GB1994/002471 WO1995013289A1 (en) | 1993-11-10 | 1994-11-10 | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases |
Publications (2)
Publication Number | Publication Date |
---|---|
NO961888D0 NO961888D0 (no) | 1996-05-09 |
NO961888L true NO961888L (no) | 1996-05-09 |
Family
ID=10744943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO961888A NO961888L (no) | 1993-11-10 | 1996-05-09 | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser |
Country Status (22)
Country | Link |
---|---|
US (1) | US5853623A (no) |
EP (1) | EP0728144B1 (no) |
JP (1) | JPH09505041A (no) |
KR (1) | KR960705843A (no) |
CN (1) | CN1134705A (no) |
AT (1) | ATE188969T1 (no) |
AU (1) | AU679286B2 (no) |
BR (1) | BR9408025A (no) |
CA (1) | CA2173470A1 (no) |
CZ (1) | CZ287780B6 (no) |
DE (1) | DE69422726T2 (no) |
DK (1) | DK0728144T3 (no) |
ES (1) | ES2143611T3 (no) |
FI (1) | FI961976A (no) |
GB (1) | GB9323165D0 (no) |
GR (1) | GR3033103T3 (no) |
HK (1) | HK1015139A1 (no) |
HU (1) | HU217344B1 (no) |
NO (1) | NO961888L (no) |
PL (1) | PL180403B1 (no) |
PT (1) | PT728144E (no) |
WO (1) | WO1995013289A1 (no) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0715619A4 (en) * | 1993-08-23 | 1997-03-19 | Immunex Corp | INHIBITORS OF TNF-ALPHA SECRETION |
GB9601042D0 (en) * | 1996-01-17 | 1996-03-20 | Smithkline Beecham Plc | Medical use |
GB9414157D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Medical use |
EP0784629B1 (en) | 1994-10-05 | 1999-04-28 | Darwin Discovery Limited | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases |
WO1996035711A1 (en) * | 1995-05-10 | 1996-11-14 | Chiroscience Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use |
US5994293A (en) * | 1995-05-10 | 1999-11-30 | Darwin Discovery Ltd. | Peptidyl compounds and their therapeutic use |
JPH11504646A (ja) * | 1995-05-10 | 1999-04-27 | カイロサイエンス・リミテッド | 金属プロテアーゼとtnfの放出を抑制するペプチド化合物およびその治療的使用 |
US5677282A (en) * | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
GB2318353B (en) * | 1995-07-20 | 1999-10-06 | British Biotech Pharm | Metalloproteinase inhibitors |
JP2008024720A (ja) * | 1995-07-26 | 2008-02-07 | Mitsubishi Chemicals Corp | ペニシラミンアミド誘導体 |
HUP0003760A3 (en) * | 1995-10-05 | 2001-05-28 | Darwin Discovery Ltd Cambridge | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use |
WO1997012861A1 (en) * | 1995-10-05 | 1997-04-10 | Chiroscience Limited | Mercaptoamide derivatives and their therapeutic use |
GB9523066D0 (en) * | 1995-11-10 | 1996-01-10 | Chiroscience Ltd | Compounds and their therapeutic use |
ATE215946T1 (de) * | 1995-11-22 | 2002-04-15 | Darwin Discovery Ltd | Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) |
NZ325939A (en) | 1996-01-23 | 2000-06-23 | Shionogi & Co | Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives |
US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
GB9607120D0 (en) * | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9607119D0 (en) * | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
US6069150A (en) * | 1996-04-04 | 2000-05-30 | F. Hoffman-La Roche Ag | Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents |
GB9607249D0 (en) * | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
GB9609702D0 (en) | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
US5852213A (en) * | 1996-07-10 | 1998-12-22 | American Cyanamid Company | Mercaptoketones and mercaptoalcohols and a process for their preparation |
CA2260859A1 (en) * | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfone metalloprotease inhibitors |
GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US6953788B1 (en) | 1996-09-19 | 2005-10-11 | Aventis Pharmaceuticals Inc. | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase |
GB9624817D0 (en) * | 1996-11-28 | 1997-01-15 | British Biotech Pharm | Metalloproteinase inhibitors |
AU741903C (en) * | 1997-03-03 | 2002-09-05 | Darwin Discovery Limited | Selective MMP inhibitors having reduced side-effects |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
WO1998039316A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
WO1998039315A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
US6696449B2 (en) | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
US6794511B2 (en) | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
ES2206903T3 (es) | 1997-03-04 | 2004-05-16 | Monsanto Company | Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco. |
US6034136A (en) * | 1997-03-20 | 2000-03-07 | Novartis Ag | Certain cyclic thio substituted acylaminoacid amide derivatives |
US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
WO1999007679A1 (en) * | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
WO1999025687A1 (en) | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010039287A1 (en) | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
AUPP508798A0 (en) * | 1998-08-05 | 1998-08-27 | Biotech Australia Pty Limited | Method of treating psoriasis |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
WO2000040552A1 (en) * | 1998-12-31 | 2000-07-13 | Aventis Pharmaceuticals Inc. | Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
US6448250B1 (en) | 1999-02-08 | 2002-09-10 | G. D. Searle & Company | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
JP2003521476A (ja) * | 1999-06-15 | 2003-07-15 | メルク エンド カムパニー インコーポレーテッド | チオール誘導体、メタロ−β−ラクタマーゼ阻害剤 |
US6869951B1 (en) | 1999-07-16 | 2005-03-22 | Pharmacia Corporation | Method of changing conformation of a matrix metalloproteinase |
US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
BR0109328A (pt) | 2000-03-21 | 2003-06-10 | Procter & Gamble | Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica |
AU2001245862A1 (en) * | 2000-03-21 | 2001-10-03 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
BR0109354A (pt) * | 2000-03-21 | 2003-04-15 | Procter & Gamble | Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
FR2823212B1 (fr) * | 2001-04-10 | 2005-12-02 | Inst Nat Sante Rech Med | Inhibiteurs de la toxine botulique de type b |
CZ20032913A3 (cs) | 2001-05-11 | 2004-05-12 | Pharmaciaácorporation | Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy |
CA2483314A1 (en) | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
EP1547617B1 (en) * | 2002-08-20 | 2010-04-28 | Astellas Pharma Inc. | Arthrodial cartilage extracellular matrix degradation inhibitor |
EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US7570250B2 (en) * | 2006-05-04 | 2009-08-04 | Yi-Ming Tseng | Control device including a ball that stores data |
EP3061460A1 (en) | 2009-04-10 | 2016-08-31 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3774858D1 (de) * | 1986-12-24 | 1992-01-09 | Beecham Group Plc | Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren. |
ATE106087T1 (de) * | 1987-03-17 | 1994-06-15 | Res Corp Technologies Inc | Synthetische inhibitoren von säugetier- collagenase. |
US5144043A (en) * | 1988-06-15 | 1992-09-01 | Centocor | Cleavable bifunctional coupling agents |
US5629343A (en) * | 1992-10-02 | 1997-05-13 | Merck & Co., Inc. | N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents |
-
1993
- 1993-11-10 GB GB939323165A patent/GB9323165D0/en active Pending
-
1994
- 1994-11-10 BR BR9408025A patent/BR9408025A/pt not_active Application Discontinuation
- 1994-11-10 DE DE69422726T patent/DE69422726T2/de not_active Expired - Fee Related
- 1994-11-10 DK DK95900237T patent/DK0728144T3/da active
- 1994-11-10 CN CN94194051A patent/CN1134705A/zh active Pending
- 1994-11-10 PL PL94314300A patent/PL180403B1/pl unknown
- 1994-11-10 JP JP7513690A patent/JPH09505041A/ja not_active Ceased
- 1994-11-10 KR KR1019960702437A patent/KR960705843A/ko active IP Right Grant
- 1994-11-10 ES ES95900237T patent/ES2143611T3/es not_active Expired - Lifetime
- 1994-11-10 EP EP95900237A patent/EP0728144B1/en not_active Expired - Lifetime
- 1994-11-10 AT AT95900237T patent/ATE188969T1/de not_active IP Right Cessation
- 1994-11-10 CA CA002173470A patent/CA2173470A1/en not_active Abandoned
- 1994-11-10 HU HU9601244A patent/HU217344B1/hu not_active IP Right Cessation
- 1994-11-10 AU AU81133/94A patent/AU679286B2/en not_active Ceased
- 1994-11-10 WO PCT/GB1994/002471 patent/WO1995013289A1/en active IP Right Grant
- 1994-11-10 PT PT95900237T patent/PT728144E/pt unknown
- 1994-11-10 CZ CZ19961349A patent/CZ287780B6/cs not_active IP Right Cessation
-
1996
- 1996-05-09 NO NO961888A patent/NO961888L/no not_active Application Discontinuation
- 1996-05-09 FI FI961976A patent/FI961976A/fi unknown
- 1996-05-10 US US08/644,383 patent/US5853623A/en not_active Expired - Fee Related
-
1998
- 1998-12-28 HK HK98115826A patent/HK1015139A1/xx not_active IP Right Cessation
-
2000
- 2000-03-29 GR GR20000400792T patent/GR3033103T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL314300A1 (en) | 1996-09-02 |
FI961976A0 (fi) | 1996-05-09 |
GB9323165D0 (en) | 1994-01-05 |
PT728144E (pt) | 2000-07-31 |
DE69422726T2 (de) | 2000-06-08 |
US5853623A (en) | 1998-12-29 |
NO961888D0 (no) | 1996-05-09 |
DE69422726D1 (de) | 2000-02-24 |
AU679286B2 (en) | 1997-06-26 |
AU8113394A (en) | 1995-05-29 |
CN1134705A (zh) | 1996-10-30 |
JPH09505041A (ja) | 1997-05-20 |
EP0728144B1 (en) | 2000-01-19 |
FI961976A (fi) | 1996-05-09 |
ATE188969T1 (de) | 2000-02-15 |
ES2143611T3 (es) | 2000-05-16 |
CZ287780B6 (en) | 2001-02-14 |
BR9408025A (pt) | 1996-12-17 |
CZ134996A3 (en) | 1996-10-16 |
CA2173470A1 (en) | 1995-05-18 |
DK0728144T3 (da) | 2000-07-03 |
PL180403B1 (pl) | 2001-01-31 |
KR960705843A (ko) | 1996-11-08 |
HU217344B1 (hu) | 2002-02-28 |
WO1995013289A1 (en) | 1995-05-18 |
HU9601244D0 (en) | 1996-07-29 |
EP0728144A1 (en) | 1996-08-28 |
GR3033103T3 (en) | 2000-08-31 |
HUT73799A (en) | 1996-09-30 |
HK1015139A1 (en) | 1999-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO961888L (no) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser | |
NO971537L (no) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser | |
NO963499L (no) | Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav | |
NO20000784L (no) | Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt | |
MX9803851A (es) | Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. | |
AU7321598A (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
NZ335981A (en) | Ketobenzamides as calpain inhibitors | |
DK0719154T3 (da) | Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel | |
AR019011A1 (es) | Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich | |
ATE266675T1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
MY129998A (en) | Saccharin derivative proteolytic enzyme inhibitors | |
MY110104A (en) | Saccharin derivative proteolytic enzyme inhibitors | |
PT705100E (pt) | Guanidinas substituidas terapeuticas | |
NO982290D0 (no) | Merkaptoalkylpeptidyl-forbindelser som har en imidazolsubstituent og deres anvendelse som inhibitorer av matriks-metalloproteinaser (MMP) og/eller tumor nekrosefaktor (TNF) | |
AU7385398A (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
ATE250030T1 (de) | Peptidverbindungen mit mmp- und tnf-hemmender wirkung | |
AP9701142A0 (en) | 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds. | |
NO972906D0 (no) | 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser | |
NO972907L (no) | 3,3-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser | |
HUP9802142A2 (hu) | Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására | |
GR920100518A (el) | Ενώσεις. | |
GR920100519A (el) | Ενώσεις. | |
MX9704733A (es) | Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |